光动力血栓法制作实验性视网膜分支静脉阻塞模型

目的应用光动力血栓法建立实验性视网膜分支静脉阻塞模型。方法12只兔12眼通过静脉内注射孟加拉红,用氪绿激光照射视网膜静脉分支,分别于照射后1h,3、7、15、30d进行眼底观察,荧光素眼底血管造影(FFA)和病理检查。结果12眼均一次造模成功,阻塞点远端静脉充血、迂曲扩张,不同程度视网膜出血和水肿。1d后3眼有视网膜中央静脉阻塞样表现,15d后5眼阻塞血管有不同程度的再通;FFA显示静脉回流障碍伴静脉内暗红色血栓;病理检查证实静脉内血栓形成。结论光动力血栓法能成功建立视网膜静脉阻塞模型并与人视网膜静脉阻塞形成近似。     

光化学法诱导兔视网膜静脉阻塞的实验研究

目的应用光化学法建立实验性兔视网膜静脉阻塞（retinal vein occlusion,RVO）模型。方法新西兰白兔10只,静脉注射孟加拉红后,激光照射视网膜静脉诱导兔眼RVO模型。分别于建模后1h、1d、3d行直接眼底镜和眼底荧光血管造影检查（fundus fluorescein angiography,FFA）。3d后摘除实验眼,行组织学检查。结果9只兔眼经光化学法诱导后,直接眼底镜、FFA检查见光凝远端视网膜静脉扩张迂曲、视网膜出血水肿等典型RVO表现;组织学检查证实光凝视网膜静脉有静脉血栓形成。结论应用光化学法能成功建立可复制、稳定的兔RVO模型,应用此动物模型,可进一步探索RVO的药物治疗并评价其疗效。     

眼外超声助溶治疗实验性视网膜静脉阻塞的初步观察

目的 探讨眼外超声（ETUS）助溶治疗实验性视网膜静脉阻塞(RVO)的有效性和安全性。 方法 将51只中华大耳白兔双眼用光动力血栓法建立RVO模型后，分别进行ETUS助溶实验和超声能量及治疗时间选择实验。前者将RVO形成后的27只兔随机分为两组，一组（15只兔）静脉内注射尿激酶（UK）（1700-2200 U溶于20 ml生理盐水中），一组（12只兔）注射生理盐水（NS）20 ml；每只兔一只眼接受ETUS治疗（1.0 W/ cm²~,20 min），另一只眼不施行ETUS作为对照。后者将RVO形成后的24只兔48只眼按超声能量随机分为0.7、1.0 W/cm²两组(每组各12只兔)，每组再按辐射时间分成8、14、20 min 3小组（每小组8只眼）。均采用1 MHz超声波100 Hz脉冲波，每天1次，连续3 d进行ETUS治疗。超声治疗后第4天行荧光素眼底血管造影(FFA)观察血管再通情况，第15天行视网膜光学显微镜和电子显微镜检查。 结果 ETUS+UK组血管再通率为66.7%，高于单纯UK组（20.0%）（P=0.025）、单纯NS组（8.3%）（P=0.005）和ETUS+NS组（8.3%）（P=0.005）；不同超声能量组的血管再通率均随辐射时间延长而明显增加（P=0.006，0.001），但不同辐射时间组超声能量对血管再通率无明显影响（P＞0.05）。接受ETUS治疗均有不同程度的视网膜组织改变和节细胞的超微结构变化，且随辐射时间增加而变得严重。 结论 ETUS能显著促进尿激酶对兔RVO血栓的溶解，同时可造成视网膜组织的明显损伤和节细胞的超微结构改变。 (中华眼底病杂志，2007，23：166-169)     

模拟失重对成年小鼠闪光视网膜电图和视网膜微循环的影响

目的:小鼠通过悬尾来模拟失重状态下体液头向重分布,然后观察视网膜电图(ERG)和视网膜微循环的变化。方法:正常成年雄性C57BL/6J小鼠随机分到3个实验组和3个对照组,最终每组6只。具体分组如下:实验1组(尾悬15d),实验2组(尾悬30d),实验3组(悬吊30d后恢复体位30d);对照1组(正常饲养15d),对照2组(正常饲养30d),对照3组(正常饲养60d)。时间满足后马上检测暗适应闪光ERG,记录混合反应和振荡电位(OPs),并进行荧光素眼底血管造影(FFA)。然后提取视网膜组织,用免疫组化法检测感光细胞视色素或视蛋白的表达,用TUNEL试剂盒检测视网膜组织细胞的凋亡情况。结果:悬吊15d组,暗适应ERG的混合反应,b波较大而OPs振幅明显降低,后者第二个子波(O 2)幅值197±33μV,15d未悬吊组336±47μV(t=-5.938,P<0.001)。悬吊30d组,小鼠ERG恢复,O 2幅值264±39μV,与30d未悬吊组308±41μV无差异(t=-1.887,P>0.05)。悬吊15d组FFA,视网膜微血管较对照组更密集,呈迂曲扩张的表现,其他实验组基本正常。各实验组感光细胞视色素或视蛋白的表达未见明显异常,视网膜未见凋亡阳性细胞。结论:模拟失重状态下体液头向重分布,短期内小鼠ERG和视网膜微循环可能受到影响,但未对视网膜产生明显的永久性损伤。     

不同色素兔光化学法诱导视网膜静脉阻塞模型的对比

目的观察并比较光化学法诱导不同色素兔视网膜静脉阻塞（RVO）模型的各自特点与差异。方法普通级有色素兔和日本大耳白兔各10只。经兔耳缘静脉注入孟加拉红（40mg／kg）后,应用倍频532激光光凝兔双眼视网膜静脉主干,制作视网膜静脉阻塞模型。所有实验兔分别于术前和光凝后15min,1、3、7、14、21、28d行眼底彩照和荧光素眼底血管造影（FFA）检查,并于光凝后1d,2组各选取2只模型兔处死,摘除眼球行病理组织切片检查,观察比较不同色素兔眼底的损伤是否存在差异;其余于光凝后28d处死,摘除眼球行光学显微镜检查。结果2组实验兔光凝后均立刻出现视网膜血流阻断现象。光凝后1d,日本大耳白兔出现显著的视网膜水肿和少量视网膜下出血,普通有色素兔则表现为视网膜下火焰状出血和较为明显的视网膜水肿。2组FFA均显示视网膜两侧动静脉主干血流被阻断。2组实验兔在1～3周时,光凝点部位血管均出现不同程度的再通,视网膜出血水肿逐渐吸收。4周时血管基本再通,FFA示普通有色素兔光凝部位血管周围出现小范围的无灌注区、色素紊乱以及血管形态的异常。病理切片显示,光凝术后1d,日本大耳白兔脉络膜中可见血栓形成,而普通有色素兔则无此现象。2组实验兔均可观察到外层视网膜水肿。光凝后28d,2组实验兔均可观察到视网膜神经节细胞核密度减少。结论通过光化学诱导法,普通有色素兔及13本大耳白兔均可成功建立RVO模型。但不同色素兔使用相同激光能量制作RVO模型,眼底损伤部位存在差异。在眼底彩照和FFA检查上,2组有显著区别,且日本大耳白兔显影较差。     

视网膜静脉阻塞的高压氧治疗电镜观察

目的 探讨高压氧治疗对视网膜静脉阻塞(RVO)后视网膜感光细胞层超微结构的影响。方法 通过氩激光光凝法制作兔眼RVO模型，对比观察高压氧治疗前后正常兔眼以及高压氧治疗(HBOT)1、3、5、10d与非HBOT RVO眼视网膜感光细胞层超微结构的改变。结果 非高压氧治疗(NHBOT)组RVO细胞线粒体外形膨大，内嵴肿胀、溶解，内质网肿胀、核糖体脱落、核膜溶解等损伤明显较HBOT组RVO眼为重；但也发现高压氧对正常兔眼视细胞线粒体造成一定损伤。结论 HBO对视网膜静脉栓塞后感光细胞层治疗有效，但应注意其毒副作用。     

bFGF诱导兔眼视网膜下新生血管形成的实验研究

目的探讨碱性成纤维细胞生长因子（bFGF）诱导青紫兰兔视网膜下新生血管动物模型的方法及可行性。方法健康成年青紫兰兔40只，随机分为2组。第1组实验组兔眼视网膜下注入0．005％（wt／vol）bFGF50μl，第2组对照组兔眼视网膜下注入0．9％生理盐水50μl，对侧眼均作为空白对照，不行视网膜下注射。术后3d，1、2、3、4、6、8、12周分别行眼底检查、摄片、眼底荧光血管造影（FFA）和吲哚青绿血管造影（ICGA），并行眼球组织病理学检查。结果视网膜下注射后所有眼即见视网膜直径4～5PD的青灰色半球形隆起，实验组与对照组分别于注射后2周和1周后平伏。术后2～12周FFA造影可见实验眼于视网膜隆起处下方早期斑点状高荧光，后期荧光增强并融合扩大。ICGA显示FFA高荧光相应部位荧光染料积存。对照组眼FFA、ICGA造影检查均未见类似表现。病理检查结果显示：视网膜下注射bFGF后2～12周，实验眼视网膜感光细胞层下有新生血管形成。结论视网膜下注入bFGF能成功诱导青紫兰兔视网膜下新生血管形成。     

视网膜电图明视负向反应在视网膜静脉阻塞中的变化

目的 观察视网膜静脉阻塞(RVO)患者视网膜电图(ERG)明视负向反应(PhNR)的变化特点.方法 对间接检眼镜、荧光素眼底血管造影(FFA)检查确诊的RVO患者30例30只患眼以及对侧健康眼进行视力、视野、闪光ERG(FERG)检查,同时选取与其性别、年龄相匹配的正常人25例50只眼作为正常组进行FERG检查.所有检查均按常规方法进行.RVO患者中,视网膜中央静脉阻塞(CRVO)患者14例14只眼、视网膜分支静脉阻塞(BRVO)患者16例16只眼.根据其病史及FFA检查结果,将其按病程时间划分为小于1个月、1～3个月、大于3个月组;另外再根据RVO分型标准及具体检查结果,将RVO患者分为缺血型和非缺血型.对比分析RVO患眼与对侧健康眼以及正常眼PhNR振幅变化及ERG其他参数指标,包括振荡电位(Ops),视锥细胞反应(Cone-a、Cone-b),视杆细胞反应(Rod-b),暗适应眼的最大反应(Max-a、Max-b),30 Hz闪烁光反应(30 Hz)的差异以及PhNR振幅变化与RVO疾病缺血类型、病程的关系.结果 PhNR振幅在CRVO患眼为(28.20±5.80)μV,BRVO患眼为(36.96±4.71)μV,对侧健眼为(61.25±3.93)μV,正常眼为(59.33±16.92)μV.CRVO组与对侧健眼、正常组比较,差异有统计学意义(F=10.69,9.80;P＜0.001),BRVO组与对侧健眼、正常组比较,差异有统计学意义(F=9.69,9.75;P＜0.001).CRVO组中缺血型PhNR值为(22.77±5.73)μV,非缺血型为(36.63±12.91)μV,二者差异有统计学意义(t=6.54,P＜0.01);BRVO组缺血型PhNR值为(32.39±13.22)μV,非缺血型为(46.73±10.43)μV,二者差异无统计学意义(t=2.12,P＜0.05);病程小于1个月组CRVO与BRVO分别为(24.58±4.60)、(27.94±15.73)μV,1～3个月组分别为(50.39±13.80)、(58.69±12.43)μV,大于3个月组为(25.40±19.94)、(34.48±16.72)μV,CRVO中1～3个月组与大于3个月组差异有统计学意义(F=4.30,P＜0.01).结论 RVO患眼的PhNR振幅较对侧健康眼以及正常对照眼明显降低,缺血型较非缺血型降低,随病程变化呈现下降、上升、下降的变化趋势.     

光化学法建立视网膜分支静脉阻塞大鼠模型及相关研究

目的：观察光化学法构建视网膜分支静脉阻塞(branch retinal vein occlusion, BRVO)大鼠模型的自然病程和不良事件。

方法：选取30只SD(Sprague Dawley)大鼠尾静脉注射孟加拉红1min后,532nm激光(80mW,100μm,100ms)于视盘颞侧视网膜静脉二级分叉处进行单光点光凝50点建立BRVO模型。分别于1、3、5、7、10、14和21d检测全视野视网膜电图(electroretinogram, ERG)、荧光素眼底血管造影(fundus fluorescein angiography, FFA)和相干光断层扫描(optical coherence tomography, OCT)。于1、5和21d各时间点随机处死2只大鼠行HE病理和血管内皮生长因子-α(vascular endothelial growth factor-α, VEGF-α)免疫组化染色。

结果：光凝后,3只大鼠死亡,3只严重出血导致视网膜大部分脱离,1只出现视网膜凹陷,1只白内障。FFA和眼底(荧光)彩照发现BRVO大鼠模型造模成功率为73%(22/30),1d时近端变粗,远端变细,3～7d光凝血管完全再通。ERG示光凝1d后暗适应3.0反应b波降低至正常眼的0.694±0.042倍,5～7d下降至最低点约为正常眼0.487±0.064倍,之后开始上升,21d上升至初始值0.708±0.0465倍。OCT和HE病理切片分别于在体和离体水平发现第1d视网膜节细胞层和外核层水肿,3～5d水肿消失且激光光凝点视网膜附近250μm外核层开始凋亡变薄,到21d外核层变薄只剩3～4层细胞。免疫组化发现激光光凝部位VEGF-α第1d表达水平大于光凝前,第5d光凝处VEGF-α表达量无明显差异,21d光凝处VEGF-α表达略低于光凝前。

结论： 激光光凝制作BRVO模型是一种切实可行的方法,其疾病的演变和发展可以部分模拟人体BRVO的进程。同时由于造模成功率较低以及激光光凝相关并发症较多,在实际使用中有待进一步改进方法。     

糖尿病视网膜病变患者合并视网膜静脉阻塞的眼底血管造影特征

目的 观察高原地区糖尿病视网膜病变(DR)例合并视网膜静脉阻塞后(RVO)眼底血管造影(FFA)的特征.方法 回顾分析高原地区患者行FFA检查的168例DR患者中合并RVO 16例18只眼的眼底图像特征及与临床的相关性.结果 16例18只眼DR合并RVO的患者中,双眼同时出现CRVO有2例4只眼,其余14例皆为单眼,其中CRVO发病率高,有9只眼,其次为颞上分支静脉阻塞,有4只眼,其它分支静脉阻塞有5只眼.从FFA图像特征发现,RVO的发病或程度与DR无平行关系,同时还可合并分支动脉阻塞.结论 DR合并RVO眼底特征与单发的DR或RVO的眼底表现略有不同,早期正确诊断对治疗意义重大.     

视网膜静脉阻塞荧光素眼底血管造影观察

目的观察视网膜静脉阻塞（RVO）的荧光素眼底血管造影（FFA）的图像特征,加深对RVO病变的认识,探讨FFA在RVO的应用。方法对我院自2006年1月至2009年12月经临床诊断为视网膜中央静脉阻塞（CRVO）和视网膜分支静脉阻塞（BRVO）患者298例（298只眼）的FFA检查结果进行回顾性分析。结果 RVO患者共298例（298只眼）。CRVO者97只眼,占32.55%;BRVO者201只眼,占67.45%。其中颞上分支静脉阻塞117只眼,占分支静脉阻塞的58.21%;半侧静脉阻塞12只眼,占5.97%。有视网膜新生血管形成32只眼,占10.74%;黄斑囊样水肿者104只眼,占35.14%;视网膜毛细血管无灌注区形成者139只眼,占46.64%。78.86%的病例发病年龄在50岁以上。结论 BRVO发病率高于CRVO;BRVO中以颞上分支静脉阻塞最常见;视网膜新生血管形成和黄斑囊样水肿是RVO的两个主要并发症。FFA对RVO的诊断、分类分型、指导治疗有重要的意义。     

维替泊芬光动力疗法治疗息肉状脉络膜血管病变的随访观察

目的 观察维替泊芬光动力疗法(photodynamic therapy,PDT)对息肉状脉络膜血管病变(polypoidal choroidal vasculopathy,PCV)的1年治疗效果.方法 9例(10只眼)经眼底彩照、荧光素眼底血管造影(fundus fluorescein angiography,FFA)和吲哚青绿血管造影(indocyanine green angiography,ICGA)确诊的PCV患者,进行常规的PDT治疗,治疗后随访第2周、1月、3月、6月、1年,观察治疗前后的视力、眼底彩照、FFA和(或)ICGA.结果 PDT治疗后1年视力提高3只眼,视力稳定6只眼,1只眼PDT治疗后出血吸收第2月复发黄斑区出血视力下降;1只眼治疗后第2周出现严重视网膜下出血,随访后渐吸收,其余患眼底出血、渗出均吸收消失.第3个月造影检查渗漏停止7只眼,3只眼轻微渗漏,末次随访3只眼仍轻微渗漏.PDT治疗过程无一例出现严重全身并发症.结论 PDT是一种安全有效的PCV治疗方法,可以短期内减轻或封闭异常血管的渗漏,促进出血、渗出吸收,稳定或提高患者视力,个别患者治疗后出现严重网膜下出血能自行吸收.

Abstract：

Objective To observe prospectively one-year's effect of photodynamic therapy (PDT)with verteporfin in polypoidal choroidal vasculopathy (PCV). Methods Nine patients (10 eyes) diagnosed as PCV according to fundus color, fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) were performed PDT. Visual acuity, Fundus appearance, FFA and/or ICGA were compared before PDT, and then at 2 weeks, 1 month, 3 months, 6 months and 12 months afier PDT.Results One year after the PDT, visual acuity was improved in 3 eyes and stabilized in 6 eyes. Visual acuity in one eye decreased again because of recurred macular bleeding. Massive subretinal hemorthage in one eye appeared two weeks after PDT and absorbed during the period of follow-up. The bleeding and exudates in the last 8 eyes were absorbed during the follow-up. At the 3 months, FFA and/or ICGA showed no Ieakage in 7 eyes, slight leakage in 3 eyes and still leakage at the final follow-up. No systemic adverse effect was found during and after PDT. Conclusions PDT offers an effective and safe way of treating PCV. PDT may relieve or stop vascular leakage, promote the elimination of the retinal hemorrhage and exudates, improve or stable the visual acuity. Massive retinal hemorrhage after PDT appears and absorbs in individual patients.     

Correlation of optical coherence tomography and fundus fluorescein angiography following photodynamic therapy for choroidal neovascular membranes

AIMS: To assess the correlation between optical coherence tomography (OCT) and leakage on fundus fluorescein angiography (FFA) following photodynamic therapy (PDT) with verteporfin for choroidal neovascularisation (CNV). METHODS: Retrospective comparative observational case series of patients who were treated with PDT for CNV from one centre. All patients had 3 monthly FFA and OCT following initial PDT to assess if further treatment was required. A pair of FFA and OCT images from the same visit at a random follow up date were taken from each patient's series and assessed separately by different observers. The presence of pigment epithelial detachment, subretinal fluid, vitreomacular traction, intraretinal fluid, absence of foveal depression, and the retinal thickness on OCT were correlated with presence of leaks on FFA. RESULTS: A total of 121 eyes of 121 patients were included. The presence of subretinal fluid, gross cystoid macular oedema, sponge-like retinal thickening and retinal thickness of more than 350 mum on OCT correlated well with leak on FFA (p value <0.01). The likelihood ratios were 3.0, 5.7, 2.7, and 3.6, respectively. The presence of a solitary foveal cyst did not correlate well with leaks on FFA. CONCLUSIONS: The presence of subretinal fluid, intraretinal fluid in the form of gross cystoid macular oedema, or sponge-like retinal thickening, or a retinal thickness more than 350 mum correlates with leaks on FFA and so suggests the need for repeat PDT.     

Deficits in the electroretinogram in neovascular age-related macular degeneration and changes during photodynamic therapy

Purpose To describe the deficits in four electroretinography (ERG) modalities in patients with neovascular age-related macular degeneration (AMD). To describe the changes in these parameters during a course of verteporfin photodynamic therapy (PDT). Methods Pattern (PERG), multifocal (mfERG) (19 segment simplified test protocol), flash ERG and flicker ERG were performed in patients with active neovascular AMD before PDT and compared to fellow eye controls using paired t-tests. Changes in ERG parameters during the 12 month treatment course were visualised using 95% confidence intervals of the median difference. The statistical significance of any changes was quantified using Wilcoxon signed ranks tests. Results Fifty patients were recruited and followed. At presentation all ERG amplitudes were reduced with greater reductions in focal as opposed to global test protocols (P < 0.05). Over the 12 month course of PDT, PERG P50 amplitude showed a general downward trend and latency remained unchanged. mfERG p1 amplitude density showed an upward trend at six months before returning to baseline by 12 months. mfERG ring 2 amplitude density was significantly increased at 12 months compared to baseline (P = 0.010). Flicker ERG latency was significantly increased at six months compared to baseline (P = 0.015). Discussion The simplified mfERG protocol was tolerated by this patient group, however, they found the full test protocol demanding. Large deficits in the retinal ERG function occur in neovascular AMD and involve retinal locations adjacent to as well as overlying choroidal neovascularisation (CNV). After PDT there is an improvement in electro-retinal function in retinal locations overlying the CNV.     

应用1/3剂量光动力学疗法治疗急性CSC

观察1/3剂量光动力学疗法（photodynamic therapy, PDT）治疗急性中心性浆液性脉络膜视网膜病变（central serous chorioretinopathy, CSC）的短期疗效。 方法：选取急性CSC患者26例26眼,行单次1/3量维替泊芬（2mg/m2）进行PDT治疗,术前和术后1,4,12wk进行最佳矫正视力和OCT的检测,且于术前、术后4wk和12wk进行眼底荧光素血管造影（FFA）,吲哚青绿血管造影（ICG）检查,观察治疗的有效性和安全性。 结果：术后1wk,26眼中有20眼（77%）视网膜下积液吸收,其余6眼（23%）视网膜下液部分吸收;术后4wk,26眼视网膜下积液全部吸收,22眼荧光渗漏完全消失,脉络膜血管高渗透性消失;术后12wk,26眼均病情平稳,无复发。治疗后1wk,最佳矫正视力从术前平均0.41升高至0.80。随访期间26眼均未见任何不良反应。 结论：1/3剂量PDT治疗急性 CSC短期内安全有效     

The changes of multifocal electroretinography in the early stage of photodynamic therapy for choroidal neovascularization

To investigate short-term changes in the multifocal electroretinography (ERG) recordings after photodynamic therapy (PDT) for choroidal neovascularization (CNV), 16 patients (17 eyes) with classic CNV confirmed by fluorescein angiography (FA) and indocyanine green angiography (ICGA), including 11 cases (12 eyes) of exudative age-related macular degeneration (AMD), two cases (two eyes) of pathological myopia and three cases (three eyes) of idiopathic causes, were treated using PDT with verteporfin. The multifocal ERGs of these patients were tested with VERIS Science^TM4.0 imaging system. The latencies and average response densities of all six ring retinal regions were measured and compared before PDT and 3 or 7 days after PDT. The latencies and amplitude densities of the N₁ and P₁ waves in all six rings remained unchanged at 3 or 7 days post-treatment (p>0.05). Therefore, there is no significant evidence to suggest an adverse effect from PDT for classic CNV on the outer retinal function in the early stage of treatment, with the aid of the multifocal ERG recordings.     

Quantitative evaluation for blood-retinal barrier breakdown in experimental retinal vein occlusion produced by photodynamic thrombosis using a new photosensitizer

Purpose. To establish a rat model of retinal vein occlusion (RVO), we applied photodynamic thrombosis using a new photosensitizer. By measuring the breakdown of the blood-retinal barrier (BRB), we evaluated the model quantitatively. We also investigated how hypertension and retinal pigment epithelium (RPE) influence the breakdown of BRB after RVO. Methods. We modified a slit lamp biomicroscope for photodynamic thrombosis. The light source was changed from white light to argon laser, which made it possible to perform fluorescein angiography (FAG) simultaneously during photodynamic thrombosis. We irradiated with a continuous diode laser to occlude three retinal veins in a rat after PAD-S31 injection. The breakdown of BRB was quantitated by measuring extravasated Evans blue dye in albino and pigmented rats. We compared hypertensive rats (SHR) to normotensive rats (WKY) and sodium iodate-treated rats to normal rats. Results. High photosensitivity of PAD-S31 made it possible to occlude any retinal veins within 120 seconds at a low dose of 10 mg/kg without retinal thermal burn at the occlusion site. Simultaneous FAG enabled us to observe the formation of thrombus during diode laser irradiation. Our measured value of intraretinal Evans blue correlated with the range of serous retinal detachment. Both albino and pigmented rats demonstrated stable and constant values of Evans blue. SHR recovered from the breakdown of BRB after venous occlusion more slowly than WKY. Sodium iodate-treated rats had smaller breakdowns of BRB and recovered earlier than normal rats. Conclusions. In this study, we established the stable and constant rat model of RVO efficiently by using a new photosensitizer. Our simultaneous FAG method was considered to have an advantage of several potential clinical applications. Our rat model of RVO allows us to study factors associated with the recovery from damage by RVO.     

小剂量维替泊芬联合光动力疗法治疗迁延性CSC

目的:观察1/3剂量维替泊芬光动力疗法治疗迁延性中心性浆液性脉络膜视网膜病变(central serous chorioretinopa-thy,CSC)的疗效。方法:反复发作的CSC患者23例(23眼),经眼底检查、眼底荧光血管造影及吲哚菁绿造影检查,接受1/3剂量维替泊芬的治疗。维替泊芬注入8min后,在FFA的引导下激光照射30s,术后随访6~12(平均9.2)mo,随访期间进行最佳矫正视力、FFA检查,对检查结果进行分析,并观察治疗的安全性。结果:在23眼中,视力均有不同程度提高,1mo后视物变形改善有21眼,6mo后视物变形均有好转,FFA检查中,1mo后活动性渗漏消失的有20眼,3mo后全部消失。OCT检查黄斑部水肿均在3mo后消失。结论:1/3剂量维替泊芬治疗迁延性CSC具有较好的疗效,但是该治疗方法的长期有效性有待于进一步的对照研究来证实。